Patents by Inventor Lawrence E. Stramm

Lawrence E. Stramm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Patent number: 6486179
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: November 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of radiation therapy
    Patent number: 6288053
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N -dimethylamino)butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: September 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Publication number: 20010001791
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Application
    Filed: January 10, 2001
    Publication date: May 24, 2001
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Patent number: 6232299
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″-(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: May 15, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Therapeutic treatment for HIV infection
    Patent number: 6107327
    Abstract: A method for treating HIV infection is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis-(3,3'-indo lyl)]-1(H)-pyrrole-2,5-dione or its acid salt.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: August 22, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapeutic treatment for skin disorders
    Patent number: 6093740
    Abstract: A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Jirousek, Lawrence E. Stramm, Louis Vignati, Douglas Kirk Ways
  • Therapeutic treatment for sexual dysfunctions
    Patent number: 6093709
    Abstract: A method for treating sexual dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly1)]-1(H)-pyrrole-2,5-dione, particularly its hydrochloride, or mesylate salt.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
    Patent number: 5962446
    Abstract: A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-?N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: October 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapeutic treatment for cardiovascular diseases
    Patent number: 5723456
    Abstract: A method for treating endothelial cell dysfunction, such as associated with cardiovascular disease are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-?N,N'-1,1'-((27"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bi s-(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: March 3, 1998
    Assignee: Eli Lilly & Company
    Inventors: Michael R. Jirousek, William Francis Heath, Jr., Douglas Kirk Ways, Lawrence E. Stramm
  • Pharmaceutical compounds
    Patent number: 5624953
    Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: April 29, 1997
    Assignee: Eli Lilly and Company
    Inventors: Samantha J. Ambler, William F. Heath, Jr., Jai Pal Singh, Colin W. Smith, Lawrence E. Stramm
  • Pharmaceutical compounds
    Patent number: 5514706
    Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Samantha J. Ambler, William F. Heath, Jr., Jai P. Singh, Colin W. Smith, Lawrence E. Stramm